Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya.

[1]  R. Madrid,et al.  Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status , 2021, Virulence.

[2]  T. Klimkait,et al.  Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre-planned analysis from the SESOTHO trial. , 2021, The Journal of antimicrobial chemotherapy.

[3]  Hansjakob Furrer,et al.  Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study , 2019, The Lancet.

[4]  A. Wensing,et al.  Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study , 2018, The lancet. HIV.

[5]  A. Esber,et al.  Persistent low level viremia predicts subsequent virologic failure. Is it time to change the 3rd 90? , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  D. Cooper,et al.  Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. , 2018, The lancet. HIV.

[7]  Diederick E Grobbee,et al.  Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. , 2017, The Lancet. Infectious diseases.

[8]  M. Wainberg,et al.  Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. , 2017, Virus research.

[9]  M. Gisslén,et al.  Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment , 2017, PloS one.

[10]  Daniel I. S. Rosenbloom,et al.  Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics , 2017, The Journal of experimental medicine.

[11]  S. Hughes,et al.  Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir , 2017, PLoS pathogens.

[12]  J. Gallant,et al.  Antiretroviral Therapy for the Prevention of HIV-1 Transmission. , 2016, The New England journal of medicine.

[13]  Pietro Vernazza,et al.  Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. , 2016, JAMA.

[14]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[15]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[16]  Art-Cc.  Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients , 2015 .

[17]  D. Bangsberg,et al.  Antiretroviral Regimen and Suboptimal Medication Adherence Are Associated With Low-Level Human Immunodeficiency Virus Viremia , 2015, Open forum infectious diseases.

[18]  P. Harrigan,et al.  HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure , 2014, AIDS.

[19]  H. Trottier,et al.  Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  C. Delaugerre,et al.  Impact of Low-Level-Viremia on HIV-1 Drug-Resistance Evolution among Antiretroviral Treated-Patients , 2012, PloS one.

[21]  G. Palù,et al.  Baseline Cellular HIV DNA Load Predicts HIV DNA Decline and Residual HIV Plasma Levels during Effective Antiretroviral Therapy , 2011, Journal of Clinical Microbiology.

[22]  R. Haubrich,et al.  Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. , 2011, The Journal of infectious diseases.

[23]  R. Kaul,et al.  Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication , 2010, AIDS.

[24]  H. Ullum,et al.  Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.